Organic compounds

Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension

Retrieved on:

Thursday, June 24, 2021

Chemical compounds, Hypertension, Organic compounds, Pulmonary hypertension, Clinical medicine, Imatinib, PAH, Iloprost, Portopulmonary hypertension

Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying

Key Points:

Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying
DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. today announced the initiation of dosing in the Phase 1 clinical trial of its drug-device combination product candidate, AER-901, an inhaled imatinib for the treatment of pulmonary arterial hypertension (PAH).
A version of this nebulizer is currently marketed to patients with a form of pulmonary arterial hypertension in Europe.
The Fox achieves deep lung deposition by administering drug only during inhalation and controlling the flow rate and volume during inspiration.
Current therapeutic options focus mostly on vasodilation and have significant shortcomings including limited efficacy, inconsistent survival benefits, and significant side effects.

LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Retrieved on:

Thursday, June 24, 2021

Dose interruptions due to an AR occurred in 45% of patients receiving LYNPARZA and dose reductions due to an AR occurred in 22% of LYNPARZA patients.

Key Points:

Dose interruptions due to an AR occurred in 45% of patients receiving LYNPARZA and dose reductions due to an AR occurred in 22% of LYNPARZA patients.
AstraZeneca and Merck are exploring additional trials in metastatic prostate cancer, including the ongoing Phase 3 PROpel trial evaluating LYNPARZA in combination with abiraterone as a first-line treatment for patients with mCRPC versus abiraterone alone.
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in approximately 1.5% of patients exposed to LYNPARZA monotherapy, and the majority of events had a fatal outcome.
Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1).

Global Flexible Pipes Market Report 2021: Market to Reach $1.1 Billion by 2027 - High-Density Polyethylene Segment to Account for $500 Million - ResearchAndMarkets.com

Retrieved on:

Wednesday, June 23, 2021

Engineering, Other Manufacturing, Manufacturing, Organic polymers, Plastics, Organic compounds, Actuarial science, Compound annual growth rate, Mathematical finance, High-density polyethylene, Polyvinyl chloride

Amid the COVID-19 crisis, the global market for Flexible Pipes estimated at US$952 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 2.6% over the analysis period 2020-2027.

Key Points:

Amid the COVID-19 crisis, the global market for Flexible Pipes estimated at US$952 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 2.6% over the analysis period 2020-2027.
High-Density Polyethylene, one of the segments analyzed in the report, is projected to record a 2.8% CAGR and reach US$512.3 Million by the end of the analysis period.
The U.S. Market is Estimated at $257.4 Million, While China is Forecast to Grow at 4.9% CAGR
The Flexible Pipes market in the U.S. is estimated at US$257.4 Million in the year 2020.
In the global Polyvinylidene Fluoride segment, USA, Canada, Japan, China and Europe will drive the 2% CAGR estimated for this segment.

Nature's Bounty® Optimal Solutions® Launches First-Ever Advanced Hair, Skin & Nails Jelly Beans

Retrieved on:

Wednesday, June 23, 2021

Branches of biology, Keratins, Organic compounds, Chemical compounds, Biotin, Cofactors, Ureas, Nail, Hair

RONKONKOMA, N.Y., June 23, 2021 /PRNewswire/ -- It's no surprise beauty starts from within and with 22% percent of consumers taking supplements to support hair, skin and nails nutrient gaps1 Nature's Bounty Optimal Solutions , the #1 brand for Hair, Skin & Nails today unveiled Advanced Hair, Skin & Nails Jelly Beans.

Key Points:

RONKONKOMA, N.Y., June 23, 2021 /PRNewswire/ -- It's no surprise beauty starts from within and with 22% percent of consumers taking supplements to support hair, skin and nails nutrient gaps1 Nature's Bounty Optimal Solutions , the #1 brand for Hair, Skin & Nails today unveiled Advanced Hair, Skin & Nails Jelly Beans.
Each serving (or 2 jelly beans) includes 6,000 mcg of Biotin to support beautiful hair, glowing skin and healthy nails, along with added Keratin and Vitamins A, C and E:
Beautiful Hair: Advanced formula with Keratin + 6,000 mcg of Biotin per serving to support healthy, beautiful hair.
*
Glowing Skin: Vegetarian formula with Vitamins A, C and E to support glowing skin.
The new Nature's Bounty Optimal Solutions Advanced Hair, Skin & Nails Jelly Beans are available now on Amazon.com and coming to Walmart, CVS, Kroger and more, shelves this summer.

Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day

Retrieved on:

Wednesday, June 23, 2021

Drugs, Organic compounds, Bristol-Myers Squibb, Chloroarenes, Clopidogrel, Hepatotoxins, Prodrugs, Sanofi, Chemical compounds

Presentations will highlight Jounces productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064.

Key Points:

Presentations will highlight Jounces productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064.
More specifically, we will discuss the monotherapy dose escalation status of our INNATE trial of JTX-8064.
Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.
Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Retrieved on:

Wednesday, June 23, 2021

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

Key Points:

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).
The primary endpoint of the study is radiographic progression-free survival (rPFS), and overall survival (OS) is a secondary endpoint.
Talazoparib is currently approved under the brand name TALZENNA for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Talazoparib is being evaluated in several ongoing clinical trials in prostate cancer, as well as other novel combinations with targeted therapies in various solid tumors.

Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic

Retrieved on:

Wednesday, June 23, 2021

Aleta Biotherapeutics (Aleta) and Cancer Research UK today announced a collaboration to advance the early phase clinical development of Aletas CAR-T cell engager candidate, ALETA-001.

Key Points:

Aleta Biotherapeutics (Aleta) and Cancer Research UK today announced a collaboration to advance the early phase clinical development of Aletas CAR-T cell engager candidate, ALETA-001.
CAR-T cell therapy is showing promising results in treating people with blood cancers who are no longer responding to current lines of treatment.
Paul Rennert, President, Co-Founder and Chief Scientific Officer, Aleta Biotherapeutics, said: We are deeply honored to be partnering with Cancer Research UK to rapidly advance our lead drug candidate, ALETA-001, into the clinic.
Six of these new agents have made it to market including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer.

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

Retrieved on:

Tuesday, June 22, 2021

Tyrosine kinase receptors, Lung cancer, Organic compounds, Quinazolines, Chemical compounds, Non-small-cell lung carcinoma, Tyrosine kinase, C-Met, Branches of biology, Tyrosine kinase inhibitors, Chloroarenes, Icotinib

Approximately 2-3% of newly diagnosed NSCLC patients have MET exon skipping 14 alterations, a specific genetic mutation.

Key Points:

Approximately 2-3% of newly diagnosed NSCLC patients have MET exon skipping 14 alterations, a specific genetic mutation.
Savolitinib is an oral, potent and selective MET TKI that has demonstrated clinical activity in advanced solid tumors.
It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations).
HUTCHMED is responsible for the manufacturing and supply of savolitinib, and AstraZeneca is responsible for its commercialization in China and worldwide.

S&B Wins Engineering and Construction Contract for Chevron Phillips Chemical’s World-Scale 1-Hexene Unit

Retrieved on:

Tuesday, June 22, 2021

S&B Engineers and Constructors (S&B) was awarded an engineering and construction contract with Chevron Phillips Chemical to engineer and build the companys second U.S. world-scale unit to produce on-purpose 1-hexene.

Key Points:

S&B Engineers and Constructors (S&B) was awarded an engineering and construction contract with Chevron Phillips Chemical to engineer and build the companys second U.S. world-scale unit to produce on-purpose 1-hexene.
View the full release here: https://www.businesswire.com/news/home/20210622005685/en/
Pictured is Chevron Phillips Chemical's 1-hexene unit at its Cedar Bayou plant in Baytown, Texas.
(Photo: Business Wire)
S&B completed Chevron Phillips Chemicals first U.S. 1-hexene unit in 2014 at its Cedar Bayou plant in Baytown, Texas.
Chevron Phillips Chemicals new 1-hexene unit will use the latest evolution of the companys proprietary, on-purpose 1-hexene technology.

Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets

Retrieved on:

Monday, June 21, 2021

Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Health, Organic compounds, COVID-19 drug development, Nucleotides, Remdesivir, COVID-19

The three real-world data analyses presented at WMF include 98,654 patients hospitalized with COVID-19.

Key Points:

The three real-world data analyses presented at WMF include 98,654 patients hospitalized with COVID-19.
Real-world evidence (RWE) analyses of Veklury from other sources are ongoing and may vary in their results or conclusions.
These real-world analyses provide clinicians with additional data on the efficacy of remdesivir (Veklury) in patients hospitalized with COVID-19, including its effect on mortality and likelihood of discharge from the hospital.
Veklury is contraindicated in patients who are allergic to Veklury or any of its components; please see below for additional Important Safety Information for Veklury.